Researchmoz added Most up-to-date research on "PharmSource - Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars - 2018 Edition" to its huge collection of research reports.
PharmSource - Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars - 2018 Edition
Summary
Biosimilars are drugs that are highly similar but not identical to branded innovator biologics: large molecule, immunogenic drugs produced from living cells. Innovator biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded drugs and their generics.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978237
There are no clinically meaningful differences in quality, safety and efficacy between biosimilars and innovator biologics. The exact definition of a biosimilar varies by regulator.
Biosimilars bring competition to expensive innovator biologics and represent a cost-saving option for payers.
More than 50 biosimilars are approved in the EU, while the FDA lags behind with 17 approvals but is catching up fast. As more innovator biologics come off-patent in the near future, this will bring a huge opportunity for biosimilar companies and for biosimilar manufacturers.
Key Questions Answered
- What biosimilars are marketed in the US and EU?
- How is biosimilar manufacturing and packaging outsourced?
- What therapies are in the biosimilar pipeline?
- In what regions is biosimilar development concentrated?
- How does biosimilar manufacturing differ by molecule type?
- When will innovator biologic patents expire, allowing biosimilar development?
- What proportion of biosimilar manufacturing is kept in-house?
- How will contract analytical testing services be affected by the rise of biosimilars?
Scope
Detailed view of -
- Marketed Innovator Biologics.
- Marketed Biosimilars.
- Innovator Biologic Patent Expiries and Waves of Biosimilar Opportunity.
- Biosimilar Clinical Pipeline.
- Existing CDMO Contracts for Biosimilars for API, Dose and Packaging.
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/pharmsource-catching-the-next-wave-how-much-have-cmos-benefited-from-biosimilars-2018-edition-report.html/toc
Reasons to buy
- This 74-page report gives important, expert insight you wont find in any other source. 20 tables and figures throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the biosimilar marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Pharmaceutical and Biotech companies involved in the development of innovator biologics or biosimilars.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.
Table of Contents
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7
4. Approved Biosimilars 10
5. Market Penetration 29
Regional Variability in Biosimilar Uptake 32
Biosimilar vs. Innovator Market Share 34
New Patient Access 35
6. The Biosimilar Pipeline 36
7. Sourcing Arrangements for Biosimilars 42
Joint Ventures 48
Capacity and scale 52
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978237
API Segmentation 52
Geography and Partnerships 53
Analytic and Testing CDMOs 54
8. Notes on Methodology 56
9. Appendix 57
9.1 Bibliography 57
9.2 Primary Research - Key Opinion Leaders in this Report 58
9.3 Additional Tables 59
9.4 About the Authors 75
Continue...
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on @ https://marketsizeinfo.blogspot.in/
PharmSource - Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars - 2018 Edition
Summary
Biosimilars are drugs that are highly similar but not identical to branded innovator biologics: large molecule, immunogenic drugs produced from living cells. Innovator biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded drugs and their generics.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978237
There are no clinically meaningful differences in quality, safety and efficacy between biosimilars and innovator biologics. The exact definition of a biosimilar varies by regulator.
Biosimilars bring competition to expensive innovator biologics and represent a cost-saving option for payers.
More than 50 biosimilars are approved in the EU, while the FDA lags behind with 17 approvals but is catching up fast. As more innovator biologics come off-patent in the near future, this will bring a huge opportunity for biosimilar companies and for biosimilar manufacturers.
Key Questions Answered
- What biosimilars are marketed in the US and EU?
- How is biosimilar manufacturing and packaging outsourced?
- What therapies are in the biosimilar pipeline?
- In what regions is biosimilar development concentrated?
- How does biosimilar manufacturing differ by molecule type?
- When will innovator biologic patents expire, allowing biosimilar development?
- What proportion of biosimilar manufacturing is kept in-house?
- How will contract analytical testing services be affected by the rise of biosimilars?
Scope
Detailed view of -
- Marketed Innovator Biologics.
- Marketed Biosimilars.
- Innovator Biologic Patent Expiries and Waves of Biosimilar Opportunity.
- Biosimilar Clinical Pipeline.
- Existing CDMO Contracts for Biosimilars for API, Dose and Packaging.
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/pharmsource-catching-the-next-wave-how-much-have-cmos-benefited-from-biosimilars-2018-edition-report.html/toc
Reasons to buy
- This 74-page report gives important, expert insight you wont find in any other source. 20 tables and figures throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the biosimilar marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Pharmaceutical and Biotech companies involved in the development of innovator biologics or biosimilars.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.
Table of Contents
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7
4. Approved Biosimilars 10
5. Market Penetration 29
Regional Variability in Biosimilar Uptake 32
Biosimilar vs. Innovator Market Share 34
New Patient Access 35
6. The Biosimilar Pipeline 36
7. Sourcing Arrangements for Biosimilars 42
Joint Ventures 48
Capacity and scale 52
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978237
API Segmentation 52
Geography and Partnerships 53
Analytic and Testing CDMOs 54
8. Notes on Methodology 56
9. Appendix 57
9.1 Bibliography 57
9.2 Primary Research - Key Opinion Leaders in this Report 58
9.3 Additional Tables 59
9.4 About the Authors 75
Continue...
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on @ https://marketsizeinfo.blogspot.in/
No comments:
Post a Comment